Company Lineage Cell Therapeutics, Inc.

Equities

LCTX

US53566P1093

Biotechnology & Medical Research

Market Closed - Nyse 04:00:00 2024-06-17 pm EDT 5-day change 1st Jan Change
0.9051 USD -1.56% Intraday chart for Lineage Cell Therapeutics, Inc. -2.15% -16.96%

Business Summary

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.

Number of employees: 72

Sales per Business

USD in Million2022Weight2023Weight Delta
Therapeutic Products
100.0 %
15 100.0 % 9 100.0 % -39.16%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
15 100.0 % 9 100.0 % -39.16%

Managers

Managers TitleAgeSince
Chief Executive Officer 53 18-09-16
Director of Finance/CFO 48 22-11-13
Chief Operating Officer - 09-12-31
Chief Tech/Sci/R&D Officer 56 18-01-31
Investor Relations Contact - -
General Counsel 43 21-08-31
Corporate Officer/Principal - 19-07-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 58 09-06-30
Chief Executive Officer 53 18-09-16
Director/Board Member 66 14-04-10
Director/Board Member 78 20-02-29
Director/Board Member 68 14-12-08
Chairman 58 14-10-03
Director/Board Member 67 21-05-03
Director/Board Member 60 21-04-19

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 188,823,975 188,001,177 ( 99.56 %) 0 99.56 %

Shareholders

NameEquities%Valuation
Broadwood Capital, Inc.
22.07 %
41,666,255 22.07 % 42 M $
Vanguard Fiduciary Trust Co.
4.435 %
8,373,771 4.435 % 8 M $
BlackRock Advisors LLC
4.330 %
8,175,661 4.330 % 8 M $
Logos Global Management LP
3.310 %
6,250,000 3.310 % 6 M $
Defender Capital LLC
2.631 %
4,967,675 2.631 % 5 M $
Geode Capital Management LLC
1.723 %
3,253,056 1.723 % 3 M $
Raffles Associates LP
1.700 %
3,209,981 1.700 % 3 M $
2,177,209 1.153 % 2 M $
Prescott General Partners LLC
0.9807 %
1,851,851 0.9807 % 2 M $
MAI Capital Management LLC
0.7896 %
1,490,862 0.7896 % 1 M $

Company contact information

Lineage Cell Therapeutics, Inc.

2173 Salk Avenue Suite 200

92008-7354, Carlsbad

+442 287 8990

http://www.lineagecell.com
address Lineage Cell Therapeutics, Inc.(LCTX)
  1. Stock Market
  2. Equities
  3. LCTX Stock
  4. Company Lineage Cell Therapeutics, Inc.